Kevin joined Insmed in July 2018, bringing more than 15 years of leadership experience in global drug development and medical affairs, including senior roles at Novartis and Sanofi Genzyme. Kevin’s work has spanned multiple therapeutic areas with a focus on immune-mediated and rare diseases, contributing to several drug approvals in the U.S. and internationally.
At Novartis, he served in leadership roles, including Vice President and Global Clinical Program Lead in Immunology Development; Head of North America Medical Affairs for Respiratory, Transplantation, and Infectious Diseases; and Vice President and Global Program Head of Neuroimmunology Development. At Sanofi Genzyme, he was Head of North America Medical Affairs for Immunology and Inflammation, and later Vice President and Global Program Head for Rare Diseases Development.
Kevin completed his residency in Internal Medicine at Beth Israel Deaconess Medical Center/Harvard Medical School, where he also served as Chief Medical Resident. He pursued fellowship training in Nephrology and Transplantation at the Hospital of the University of Pennsylvania, earning a Master of Science in Clinical Epidemiology from the University of Pennsylvania. He remained on the faculty at Penn’s Perelman School of Medicine, where he was appointed Senior Scholar at the Center for Clinical Epidemiology and Biostatistics. His academic work included NIH-funded research and original publications in leading journals, including The New England Journal of Medicine and The Journal of the American Medical Association.
Your Privacy Choices